| Home | Log In | Register | Our Services | My Account | Contact | Help |
- 27 Sep 2010 18:51
- 42 of 61
- 27 Sep 2010 21:50
- 43 of 61
- 13 Aug 2012 12:08
- 47 of 61
- 14 Aug 2012 11:38
- 48 of 61
- 14 Aug 2012 12:49
- 49 of 61
- 07 Sep 2012 17:20
- 50 of 61
- 01 Oct 2012 09:11
- 51 of 61
- 04 Jun 2013 10:05
- 53 of 61
- 07 Sep 2015 22:23
- 55 of 61
- 22 Feb 2016 21:21
- 56 of 61
- 07 Mar 2016 17:27
- 57 of 61
- 11 Jul 2016 07:41
- 58 of 61
- 21 Jun 2017 22:39
- 59 of 61
- 21 Jun 2017 22:41
- 60 of 61
- 06 Apr 2018 10:50
- 61 of 61
The evening is a perfect opportunity for existing shareholders or potential investors to hear from those that matter, the directors running the companies and fund managers managing their fund. Who better to explain the future potential and strategy.
Monday 21 May 2018
Venue:Novotel Tower Bridge, London EC3N 2NR, 10 Pepys Street, London, EC3N 2NR
Event Timings:| 18.00 | Registration and coffee | |
| 18.30 | Presentations • Gerard Kisbey-Green, CEO - Goldplat (GDP) • Stewart Cazier, Head of Retail - ThinCats • Cameron Reynolds, CEO - VolitionRx | |
| 20.30 | Drinks reception and canapés | |
| 21.30 | Close |
ThinCats is one of the pioneers of the peer-to-peer business lending industry; specialising in loans with security and linking retail and institutional investors directly with established business borrowers to provide an alternative to high street banks. The company was founded in the aftermath of the global financial crisis, with the aim of offering loans to UK businesses struggling to access funding through traditional channels, whilst providing investors with attractive rates of interest unavailable through many conventional investment portfolios. A key element of the ThinCats ethos has always been to avoid the algorithm-led decision making often used by banks; the founders were keen to hear the stories behind the borrowers’ investment needs, and assess each one based on its merits. The company continues to work in this way, harnessing the knowledge of financial experts to assess each loan application, thereby encouraging growth, development and innovation in UK business.
|
Volition is a multi-national life sciences company developing simple, easy to use blood-based cancer tests to accurately diagnose a range of cancers. The tests are based on the science of Nucleosomics®, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. As cancer screening programs become more widespread, Volition's products aim to help to diagnose a range of cancers quickly, simply, accurately and cost effectively. Early diagnosis has the potential to not only prolong the life of patients, but also to improve their quality of life. Volition's research and development activities are currently centered in Belgium, with additional offices in London, Texas and Singapore, as the company focuses on bringing its diagnostic products to market first in Europe, then in the U.S. and ultimately, worldwide. |